SPORE in Pancreatic Cancer
Linda Jin, MD, a general surgery resident, and William Hawkins, MD, a professor of surgery, both at Washington University School of Medicine in St. Louis, work in the lab. Hawkins is principal investigator of a $10.4 million grant aimed at developing new treatments for pancreatic cancer.
Pancreatic cancer is the fourth leading cause of cancer death in the United States. Washington University’s Pancreas SPORE is designed to address the deadliest form of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC), by collaborating with multiple departments, programs and other institutions in interdisciplinary translational research. The Pancreas SPORE investigators have expertise in basic and clinical sciences, and individual expertise in immunology, drug development, genomics and imaging to develop novel therapeutic approaches to PDAC.
The Pancreas SPORE includes four research programs, an administrative core and two shared-resource cores, and research opportunities for collaboration including developmental research and career enhancement programs. Clinical trials are an important and active part of the Pancreas SPORE.
The long-term goal of the Pancreas SPORE is to improve PDAC patient survival. To achieve this goal, our SPORE will collaborate both within Washington University and with external institutions. Our investigators expect no singular approach to solve PDAC and fully commit to supporting young investigators and evaluating new ideas. Our SPORE will provide access to pancreas cancer-specific resources to further this goal.
Visit the Washington University Pancreas SPORE website (you will be taken off the Siteman Cancer Center website).